Acumen Pharmaceuticals, Inc. Common Stock (ABOS) is a publicly traded Healthcare sector company. As of July 7, 2026, ABOS trades at $2.50 with a market cap of $197.90M and a P/E ratio of -1.35. ABOS moved -5.43% today. Year to date, ABOS is +33.83%; over the trailing twelve months it is +130.17%. Its 52-week range spans $0.86 to $3.60. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ABOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ABOS, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $2.50 |
| Market Cap | $197.90M |
| P/E Ratio | -1.35 |
| EPS | $-2.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.60 |
| 52-Week Low | $0.86 |
| Volume | 108.55K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-121.33M |
| Gross Margin | 0.00% |
1 analysts cover ABOS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.